Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation

Yo Ichi Yamashita, Mitsuo Shimada, Ryosuke Minagawa, Eiji Tsujita, Norifumi Harimoto, Shinji Tanaka, Ken Shirabe, Jun Ichi Miyazaki, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

We developed a new potent nonviral gene transfer method into mouse muscles in vivo named "electrosonoporation." We tried in this report to treat murine orthotopic hepatocellular carcinoma (HCC) by muscle-targeted mouse interleukin-12 (mIL-12) gene transfer using in vivo electrosonoporation. I.m. administration of the mIL-12 gene with electrosonoporation elevated serum IL-12 and IFN-γ and significantly prolonged the survival periods with both growth inhibition of orthotopic HCC and inhibition of spontaneous lung metastasis. The IL-12 gene therapy reduced the number of microvessels and induced more Mac-1-positive cells into HCC. These results show that muscle-targeted mIL-12 gene therapy for orthotopic HCC using in vivo electrosonoporation is very efficient and is thus promising for further clinical trial.

元の言語英語
ページ(範囲)1177-1182
ページ数6
ジャーナルMolecular Cancer Therapeutics
3
発行部数9
出版物ステータス出版済み - 9 1 2004

Fingerprint

Interleukin-12
Genetic Therapy
Hepatocellular Carcinoma
Muscles
Genes
Microvessels
Clinical Trials
Neoplasm Metastasis
Lung
Growth
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Yamashita, Y. I., Shimada, M., Minagawa, R., Tsujita, E., Harimoto, N., Tanaka, S., ... Maehara, Y. (2004). Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. Molecular Cancer Therapeutics, 3(9), 1177-1182.

Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. / Yamashita, Yo Ichi; Shimada, Mitsuo; Minagawa, Ryosuke; Tsujita, Eiji; Harimoto, Norifumi; Tanaka, Shinji; Shirabe, Ken; Miyazaki, Jun Ichi; Maehara, Yoshihiko.

:: Molecular Cancer Therapeutics, 巻 3, 番号 9, 01.09.2004, p. 1177-1182.

研究成果: ジャーナルへの寄稿記事

Yamashita, YI, Shimada, M, Minagawa, R, Tsujita, E, Harimoto, N, Tanaka, S, Shirabe, K, Miyazaki, JI & Maehara, Y 2004, 'Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation', Molecular Cancer Therapeutics, 巻. 3, 番号 9, pp. 1177-1182.
Yamashita YI, Shimada M, Minagawa R, Tsujita E, Harimoto N, Tanaka S その他. Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. Molecular Cancer Therapeutics. 2004 9 1;3(9):1177-1182.
Yamashita, Yo Ichi ; Shimada, Mitsuo ; Minagawa, Ryosuke ; Tsujita, Eiji ; Harimoto, Norifumi ; Tanaka, Shinji ; Shirabe, Ken ; Miyazaki, Jun Ichi ; Maehara, Yoshihiko. / Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. :: Molecular Cancer Therapeutics. 2004 ; 巻 3, 番号 9. pp. 1177-1182.
@article{4e5c36c1cdc34340b159c58d3388eff8,
title = "Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation",
abstract = "We developed a new potent nonviral gene transfer method into mouse muscles in vivo named {"}electrosonoporation.{"} We tried in this report to treat murine orthotopic hepatocellular carcinoma (HCC) by muscle-targeted mouse interleukin-12 (mIL-12) gene transfer using in vivo electrosonoporation. I.m. administration of the mIL-12 gene with electrosonoporation elevated serum IL-12 and IFN-γ and significantly prolonged the survival periods with both growth inhibition of orthotopic HCC and inhibition of spontaneous lung metastasis. The IL-12 gene therapy reduced the number of microvessels and induced more Mac-1-positive cells into HCC. These results show that muscle-targeted mIL-12 gene therapy for orthotopic HCC using in vivo electrosonoporation is very efficient and is thus promising for further clinical trial.",
author = "Yamashita, {Yo Ichi} and Mitsuo Shimada and Ryosuke Minagawa and Eiji Tsujita and Norifumi Harimoto and Shinji Tanaka and Ken Shirabe and Miyazaki, {Jun Ichi} and Yoshihiko Maehara",
year = "2004",
month = "9",
day = "1",
language = "English",
volume = "3",
pages = "1177--1182",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation

AU - Yamashita, Yo Ichi

AU - Shimada, Mitsuo

AU - Minagawa, Ryosuke

AU - Tsujita, Eiji

AU - Harimoto, Norifumi

AU - Tanaka, Shinji

AU - Shirabe, Ken

AU - Miyazaki, Jun Ichi

AU - Maehara, Yoshihiko

PY - 2004/9/1

Y1 - 2004/9/1

N2 - We developed a new potent nonviral gene transfer method into mouse muscles in vivo named "electrosonoporation." We tried in this report to treat murine orthotopic hepatocellular carcinoma (HCC) by muscle-targeted mouse interleukin-12 (mIL-12) gene transfer using in vivo electrosonoporation. I.m. administration of the mIL-12 gene with electrosonoporation elevated serum IL-12 and IFN-γ and significantly prolonged the survival periods with both growth inhibition of orthotopic HCC and inhibition of spontaneous lung metastasis. The IL-12 gene therapy reduced the number of microvessels and induced more Mac-1-positive cells into HCC. These results show that muscle-targeted mIL-12 gene therapy for orthotopic HCC using in vivo electrosonoporation is very efficient and is thus promising for further clinical trial.

AB - We developed a new potent nonviral gene transfer method into mouse muscles in vivo named "electrosonoporation." We tried in this report to treat murine orthotopic hepatocellular carcinoma (HCC) by muscle-targeted mouse interleukin-12 (mIL-12) gene transfer using in vivo electrosonoporation. I.m. administration of the mIL-12 gene with electrosonoporation elevated serum IL-12 and IFN-γ and significantly prolonged the survival periods with both growth inhibition of orthotopic HCC and inhibition of spontaneous lung metastasis. The IL-12 gene therapy reduced the number of microvessels and induced more Mac-1-positive cells into HCC. These results show that muscle-targeted mIL-12 gene therapy for orthotopic HCC using in vivo electrosonoporation is very efficient and is thus promising for further clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=4644323918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644323918&partnerID=8YFLogxK

M3 - Article

C2 - 15367712

AN - SCOPUS:4644323918

VL - 3

SP - 1177

EP - 1182

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -